The summary presented herein covers recommendations on the early detection of prostate cancer and provides a framework to facilitate clinical decision-making in the implementation of prostate cancer screening, biopsy, and follow-up. This is Part II of a two-part series focusing on initial and repeat biopsies, and biopsy technique. Please refer to Part I for discussion of initial prostate cancer screening recommendations.
The systematic review utilized to inform this guideline was conducted by an independent methodological consultant. The systematic review was based on searches in Ovid MEDLINE and Embase and Cochrane Database of Systematic Reviews (January 1, 2000-November 21, 2022). Searches were supplemented by reviewing reference lists of relevant articles.
The Early Detection of Prostate Cancer Panel developed evidence- and consensus-based guideline statements to provide guidance in prostate cancer screening, initial and repeat biopsies, and biopsy technique.
The evaluation of prostate cancer risk should be focused on the detection of clinically significant prostate cancer (grade group 2 or higher [GG2+]). The use of laboratory biomarkers, prostate MRI, and biopsy techniques described herein may improve detection and safety when a prostate biopsy is deemed necessary following prostate cancer screening.
The Journal of urology. 2023 Apr 25 [Epub ahead of print]
John T Wei, Daniel Barocas, Sigrid Carlsson, Fergus Coakley, Scott Eggener, Ruth Etzioni, Samson W Fine, Misop Han, Sennett K Kim, Erin Kirkby, Badrinath R Konety, Martin Miner, Kelvin Moses, Merel G Nissenberg, Peter A Pinto, Simpa S Salami, Lesley Souter, Ian M Thompson, Daniel W Lin
University of Michigan, Ann Arbor, Michigan., Vanderbilt University, Nashville, Tennessee., Memorial Sloan Kettering Cancer Center, New York, New York., Oregon Health & Science University, Portland, Oregon., University of Chicago, Chicago, Illinois., Fred Hutchinson Cancer Center, Seattle, Washington., Johns Hopkins University, Baltimore, Maryland., American Urological Association, Linthicum, Maryland., Allina Health., Brown University, Providence, Rhode Island., National Alliance of State Prostate Cancer Coalitions., National Institutes of Health, Bethesda, Maryland., Nomadic EBM Methodology., CHRISTUS Health., University of Washington, Seattle, Washington.